VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis.
Pasmant
Eric
E
Department of Haematology, Beaujon hospital, AP-HP, Clichy, France. eric.pasmant@bjn.aphp.fr
de Beauvoir
Charlotte
C
Plessier
Aurélie
A
Labreuche
Julien
J
Bezeaud
Annie
A
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D006502:Budd-Chiari Syndrome / Q000188:drug therapy / Q000235:genetics*; D015331:Cohort Studies; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D011110:Polymorphism, Genetic; D014812:Vitamin K / Q000037:antagonists & inhibitors; D064417:Vitamin K Epoxide Reductases
D000925:Anticoagulants; D014812:Vitamin K; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases